Tempest Therapeutics Secures $2.5M via Warrant-Linked Private Placement

summarizeSummary

Tempest Therapeutics raised $2.5 million through a private placement of pre-funded warrants and common warrants, providing runway for a cash-strapped biotech but creating substantial potential dilution.

check_boxKey Events · Financing and Capital Events · TPST

• Private Placement Closed

  Issued pre-funded warrants for 3,105,591 shares plus Series C and D warrants for 6,211,182 shares at $0.804 per unit, raising approximately $2.5 million in gross proceeds.

• Warrant Structure Creates Dilution Overhang

  Common warrants exercisable at $0.805 per share, subject to stockholder approval; if fully exercised, total potential issuance reaches 9.3 million shares — roughly 65% of current outstanding shares.

• Cash Runway Extension

  Proceeds provide working capital for a company that reported only $0.8 million in cash as of August 13, 2026, extending operations but not resolving the going concern warning.

• Stockholder Approval Required

  Company must seek stockholder approval within 90 days for common warrant exercise; if not obtained at first meeting, must call meetings every 90 days until approval or warrant expiration.

auto_awesomeAnalysis · TPST · Life Sciences

On September 15, 2026, Tempest Therapeutics closed a $2.5 million private placement, issuing pre-funded warrants for 3.1 million shares and Series C and D warrants for an additional 6.2 million shares. The deal provides critical near-term liquidity for a company that reported only $0.8 million in cash as of August 13, 2026. However, the warrant structure creates significant potential dilution—up to 9.3 million shares if all warrants are exercised, versus roughly 14.2 million shares currently outstanding. The common warrants require stockholder approval before exercise, adding a governance step that could delay or complicate the capital raise.